CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis-Reference-Cited by-同舟云学术

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

Published:2016-07-15 Issue:2 Volume:80 Page:294-300
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Gerdes Lisa Ann¹^ORCID,Held Kathrin¹,Beltrán Eduardo¹,Berking Carola²,Prinz Jörg C.²,Junker Andreas³⁴,Tietze Julia K.²,Ertl‐Wagner Birgit⁵,Straube Andreas⁶,Kümpfel Tania¹,Dornmair Klaus¹,Hohlfeld Reinhard¹⁷

Affiliation:

1. Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Grosshadern‐Martinsried Campus, Ludwig Maximilian UniversityMunich

2. Department of Dermatology and AllergologyLudwig Maximilian UniversityMunich

3. Department of NeuropathologyUniversity of GöttingenGöttingen

4. Department of NeuropathologyUniversity of Duisburg‐EssenEssen

5. Department of RadiologyGrosshadern Medical Campus, Ludwig Maximilian UniversityMunich

6. Department of NeurologyLudwig Maximilian UniversityMunich

7. Munich Cluster of Systems Neurology (SyNergy)Munich Germany

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.24715

Reference26 articles.

1. The genetics of multiple sclerosis: an up-to-date review

2. Immunopathology of multiple sclerosis

3. Multiple sclerosis

4. Multiple sclerosis genetics

5. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports;Current Drug Safety;2024-08

2. Paraneoplastic Neurologic Disorders;CONTINUUM: Lifelong Learning in Neurology;2024-08

3. Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors;Biomedicines;2024-06-13

4. Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

5. Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-03